Odonate Therapeutics (NASDAQ:ODT) and Catalyst Biosciences (NASDAQ:CBIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.

Profitability

This table compares Odonate Therapeutics and Catalyst Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Odonate Therapeutics N/A -42.85% -40.38%
Catalyst Biosciences N/A -22.67% -21.79%

Risk & Volatility

Odonate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 2.51, indicating that its share price is 151% more volatile than the S&P 500.

Institutional & Insider Ownership

91.8% of Odonate Therapeutics shares are held by institutional investors. Comparatively, 67.6% of Catalyst Biosciences shares are held by institutional investors. 49.0% of Odonate Therapeutics shares are held by company insiders. Comparatively, 3.1% of Catalyst Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Odonate Therapeutics and Catalyst Biosciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Odonate Therapeutics N/A N/A -$32.74 million ($2.31) -7.15
Catalyst Biosciences $1.02 million 104.60 -$21.56 million ($7.45) -1.20

Catalyst Biosciences has higher revenue and earnings than Odonate Therapeutics. Odonate Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Odonate Therapeutics and Catalyst Biosciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Odonate Therapeutics 0 0 0 0 N/A
Catalyst Biosciences 0 1 3 0 2.75

Catalyst Biosciences has a consensus price target of $23.88, suggesting a potential upside of 167.36%. Given Catalyst Biosciences’ higher probable upside, analysts clearly believe Catalyst Biosciences is more favorable than Odonate Therapeutics.

Summary

Catalyst Biosciences beats Odonate Therapeutics on 8 of the 11 factors compared between the two stocks.

Odonate Therapeutics Company Profile

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc. also conducting a Phase III study in MBC, which is known as CONTESSA. The company was founded in 2013 and is based in San Diego, California.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing CB 2679d/ISU304, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis for development and manufacturing of the Factor IX products through Phase I/II clinical trials. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company is headquartered in South San Francisco, California.

Receive News & Ratings for Odonate Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Odonate Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *